BHPA Inc (PK) (BHPA) News

Hope finra denies it.

5 employees. No revenue. Product portfolio looks sounds like bandages. Reverse split filed for approval. Might help to explain the low to no volume.

Many use as a checkbook currency at shareholders expense. Doesn’t even appear the new company has revenue etc. with the reverse shareholders could get diluted with roughly 500 unallocated shares. Horrible if so.

Who knows I don’t understand this OTC anymore….

Can understand selling here, not sure why there would be buying.

Yeah. It’ll be back into .000s post RS soon if they’re able to do this. They’ve been scamming here for a while so idk if finra enables more of it

Agree, contact them. Where did the crypto go? Why no updates from the new company? Now a pending reverse etc. Horrible.

Yes! Contact them... this thing has reeked of scam for years now.

Yes, I remember the disappearance of the bitcoin - where did it go. We need to find out.

Yes, there seems to be an affiliation with Hestia, Bhpa - etc.

Time to investigate here.

Yguan, do you have a connection/affiliation with Bhpa, Hsta, etc.

That guy is obviously a shill for Hestia. They worked a deal with Aquiva to move into Bhpa. Check his birthdate and post history. But same principal is involved in all three companies. Total b bullshit. Remember all the stolen Bitcoin?
I’m thinking about contacting the sec about this thievery. Might as well not make it easy for the Asians to come in here and just mess with us.

Have you read the last page of the Q. They are changing the name, 70k reverse split,decreasing the authorized from 6 billion to 750m etc.

For every 1 m shares owned pre split you will own 14,285 post split.

Post reverse split there will be roughly 5.5 million shares outstanding. With the new authorized count to be 760 million shares, this gives the company just under 700m shares to dilute/use/issue as they want.

This picture makes it clear to me why there is little buying - seriously, the company has zero sales and can dilute up to 750m shares while current holders will only own 5.5 million shares post split. No thank you.

Wouldn’t be surprised if we see heavy selling with the price possibly going into the trips.

My opinions.

Dang… what a mess here….0027? Ooof… I hope finra denies them … they won’t approve anything until all the filings are accurate with no gaps

Correction, the outstanding shares post reverse will be roughly 55 million shares. With the authorized being 750 million shares, this leaves them with roughly 695 million shares to use/dilute etc.

54,661,165 shares. Almost 55m outstanding post reverse. Ps. I had a senior moment. lol.

OS will be 5.4+ mil or 54+ mil ?

Oh, I too am familiar with those senior moments. Lol.

The authorized share count will not be impacted by a reverse split and they will remain at 750 million shares.

The pre split outstanding share count is 3,826,281,559. Post split the outstanding share count would be reduced to 5,466,116 shares.

The authorized share count will remain at 750m shares post split with 5,466,116 issued and outstanding and 744,533,884 shares unallocated and available for the company to use as they deem appropriate.

Must have been another one of those "senior moments" ... My bad .

So , that would put the AS at 54,661,165 and the float at 373,004 .. with shares at .28 .

It looks like you applied the 1 for 70 reverse split against an authorized count of 750k. Should be 750m.

However, the above really doesn’t matter as the reverse split will not apply to the authorized shares, only the outstanding shares. The authorized will remain at 750m shares post split.

So , while we wait , I did a little look-see ...

When you put Aquiva Group Inc. into the search box on this website esos.nv.gov ....

you get the name change , share count reduction but nothing about any split .

If they were to NOW enact the 1 for 70 split the AS would be reduced to 10,714 .

At the post r/s price of .28 the "market cap" would then become $3000.00 ?

As usual , something is amiss ... >> M

Last page of the Q. I think they have been filed - approved by Bhpa board and submitted to otc/firna etc.

Where do you find that these "events" have been "approved" ?

I only see where they have been "filed" .

So the reported float goes from less than 400k to over 26 million. Shocker that it could be so off for so long. Ps reverse split approved - 70:1 and a reduction in authorized to 750m shares.

So the reported float goes from less than 400k to over 26 million. Shocker that it could be so off for so long.

Thanks. Uggg. Sounds like they have zero revenue and won’t launch for sometime. Wonder who was buying today - and why. Still holding but not excited.

Float shares are not provided by the company. OTCmarkets get it from other sources. The company's quarterly report needs to match OTCmarkets' data. However it looks like it's been corrected.

Yep… that’s why finra won’t approve any changes… but may not matter anyway… bottom falling out here now with no support

For now the company can’t even accurately report the float - the recent Q is way off in reporting the float - by millions and millions of shares.

Agree on all points…. Frustrating….. they’ve been quiet for years here

The new company should address shareholders. Why the share mods - both the reverse and reduction in authorized. Update on product intro - what are the benefits, will they secure a patent, where is the market, what is the rollout plan - or are they going to try and sell the company to a large pharma - etc.

More whacks today… hmm…

Yep…. 0 transparency besides incorrect filings

And we know so little about the new company. What makes their products special. How do they plan on marketing their soon to be released products - how and to what markets. Lot’s of questions.

Yeah idk what’s going on here. Finra won’t approve anything with incorrect filings so they need to clear a lot up first

They have already filed for a reverse split 70:1. They have also filed for a reduction in authorized from 6 billion to 750 million shares.

The outstanding share count reported in the latest q is incorrect. This needs to be corrected as well.

Didn’t read the report yet. So if they are doing a r/s we are all toast here. It will just be another dilution machine.

Anyone else read page 20 of the Q - link below.

Among other things, a 70:1 reverse split and the lowering of the authorized from 6 billion to 750 million. Thoughts? Sure appears the float reported of 373,005 shares is inaccurate as I alone own more than the reported float. Just imagine a 70:1 reverse applied to the float - would end up with a float of 5,328 shares. Lol. But clearly the reported float is inaccurate.

https://www.otcmarkets.com/otcapi/company/financial-report/409557/content

Inaccurate Q report. How in the heck could they have so grossly inaccurately report the float. Come on Bhpa, get your act together. Amend the Q with accurate data.

Lol same…

Bullshit on the number of shares reported in the public float - 373,005 shares. I own more than this amount - alot more.

https://www.otcmarkets.com/otcapi/company/financial-report/409557/content

Anyone know when the next filing is due? Tia.

https://www.linkedin.com/company/prisma-biotech


Apparently this ceo is involved in many ventures. Not sure how or if that company is related to this company.

Fingers crossed. Hopefully they introduce products soon and have partners on the distribution/buy side.

Yep, agreed. Hopefully back over 01+ soon and then pr with updates

My guess is someone familiar with the company is buying. Looks like product introduction is starting before end of year. Wonder if they have aligned partners - big box etc. who knows, just guessing but yes, more buying today.

More action today… let’s see if bids move up

Hopefully we find out soon…. Wasn’t huge volume yesterday … but much more than usual.

From a friend

Kevin Tseng
From:kevin-tseng@prismabiotech.com.tw
To:XXXXX XXXXXXX
Fri, Jul 19 at 6:27 AM
Hi XXXXXXXX

Thanks for your interest in our stock.
We have used our proprietary technology called HIPNA to develop a kind of multi-functional hydrogel material AQUIPHER which can be applied to a variety of market segments, including wound care, skin care and transdermal drug delivery. We are preparing to launch our first stage of products before end of this year. With several leading features, we believe our products can attract the industry’s attention and have strong potential to grow revenues in north American market.

With all the best,
Kevin Tseng

We know so little so who is buying and why? An insider?

Who even knows if the company has any revenue. What makes their products better than simple bandaids. How are they promoting their products and do they have any big box stores of interest.